Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature.

Abstract

Sarcoidosis is a multisystem granulomatous disease that affects multiple organs in adults between 20 and 50 years old. Interferon alpha (IFN-α) is an immunomodulator that has been used in a wide range of diseases, including hepatitis C virus infection, multiple sclerosis, and other types of neoplasias, including leukemia, lymphoma, Kaposi's sarcoma, and melanoma. Standard IFN-α-induced sarcoidosis has been reported, but there are few reports of cutaneous sarcoidosis with pegylated IFN-α therapy. We present a new case of cutaneous sarcoidosis after treatment with pegylated IFN, and a review of the literature.

• Authors: Verónica López, Inmaculada Molina, Carlos Monteagudo, Esperanza Jordá
• Journal: International journal of dermatology (Int J Dermatol) Vol. 50 Issue 3 Pg. 287-91 (Mar 2011) ISSN: 1365-4632 [Electronic] England
• PMID: 21342161 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: © 2011 The International Society of Dermatology.

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Polyethylene Glycols
• Ribavirin
• peginterferon alfa-2a

Topics

• Antiviral Agents (adverse effects)
• Hepatitis C, Chronic (drug therapy)
• Humans
• Interferon alpha-2
• Interferon-alpha (adverse effects)
• Male
• Middle Aged
• Polyethylene Glycols (adverse effects)
• Recombinant Proteins
• Ribavirin (adverse effects)
• Sarcoidosis (chemically induced)
• Skin Diseases (chemically induced)